drugset / Trial / NCT06408935
Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy of guselkumab in healing of all layers of the digestive tract (transmural healing) with the help of a score called Magnetic Resonance Index of Activity (MaRIA) based on a scan at Week 48.
Timeline
- Start
- 2024-04-17
- Primary completion
- 2027-06-08
- Completion
- 2028-03-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Guselkumab | Monoclonal antibody | 100 mg | Intravenous |
| Subject | Guselkumab | Monoclonal antibody | 200 mg | Intravenous |